Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Rotselaar – page 6

1 981 clinical trials in Rotselaar, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rotselaar at a glance
1 981
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 981 trials in Rotselaar

Open in trial search

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tozorakimab
  • Sponsor:AstraZeneca AB

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on Spesolimab for Adults with Pyoderma Gangrenosum Requiring Systemic Therapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Study on Lebrikizumab for Adults with Chronic Rhinosinusitis and Nasal Polyps Using Intranasal Corticosteroids

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Dermatomyositis+1

Recruiting

Study on Anifrolumab for Adults with Polymyositis or Dermatomyositis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Pegozafermin Treatment for Patients with Liver Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study of Elafibranor for Adults with Primary Biliary Cholangitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Rotselaar

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This study explores alternative approaches for managing functional dyspepsia and related conditions.

  • Primary Care Management
  • Medication Optimization
  • Digestive Health

The research evaluates the effectiveness of on-demand medication use and alternative treatments, aiming to improve long-term patient care strategies in treating gastric acid-related conditions.

02 Therapeutic Optimization

Investigation into optimal medication reduction strategies, comparing alginate-based therapy with traditional stepping-down approaches. The study addresses common digestive conditions including heartburn and reflux.

  • Treatment Alternatives
  • Patient-Centered Care
  • Medication Management

This research aims to establish evidence-based guidelines for discontinuing long-term acid suppression therapy while maintaining patient comfort and health outcomes.

03 Clinical Care Innovation

Assessment of novel approaches in managing chronic acid reflux conditions, focusing on patient-oriented solutions and sustainable treatment strategies in primary care settings.

  • Quality of Life Improvement
  • Sustainable Healthcare
  • Evidence-Based Practice

The research explores comparative effectiveness of different therapeutic approaches, aiming to optimize long-term patient outcomes in digestive health management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.